GW Pharmaceuticals: A Cannabinoid Product Succeeds in Treating a Resistant Epilepsy. Stock Price Doubled.
March 14, 2016
0
London, UK, 14 March 2016: GW Pharmaceuticals (GWPH), is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. The firm announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex®(cannabidiol or CBD) for the treatment of Dravet syndrome. In this study, the firm’s product, Epidiolex, achieved the primary endpoint of a significant reduction in convulsive …